Fennec Pharmaceuticals Inc.

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals' third quarter 2024 earnings and corporate update conference call. At this time, all participants are in listen-only mode. Later, we'll conduct question and answer session, and instructions on how to participate will begin at that time. If anyone requires operator assistance during today's call, please press star zero on your telephone. As a reminder, today's conference call is being recorded. Now, I would like to turn the conference over to FENIC's Chief Financial Officer, Robert Andrade.

Thank you, Operator, and good morning, everyone. We appreciate you joining us today for FENIC Pharmaceuticals' third quarter 2024 earnings conference call, during which we will review our financial results as well as provide a general business update. Joining me from FENIC this morning is our Chief Executive Officer and Board Member, Jeff Hackman. As a reminder, Jeff joined Fennec on August 5th, and in just a few short months has made significant progress in positioning the company for near-term and future growth and sustainability. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. Now, with that behind us, I will now turn the call over to Jeff Hackman. Jeff?

Thank you, Robert, and good morning, everyone. This morning, I'm going to discuss the recent progress that we've been making along with some key developments, including developments around market expansion, our academic endorsements, new demographic interests, our educational investments, our operational efficiencies, the strengthening of our leadership, and most importantly, our execution. all of which will drive meaningful growth in the quarters ahead. So since joining Fennec in August, as Robert mentioned, I've conducted several planning sessions with our senior leadership teams across multiple functional areas. I've done a detailed deep dive in each territory of the business. I know where we are getting our business, and I know where we are not. We're making adjustments including selective modifications to some of the historical spending that we've been doing. We also are going to align our goals and our actions with the company's long-term vision to ensure that all eligible platinum treated cancer patients are spared further hardships by protecting their ears against the profound threat of hearing loss. I've put into place some strategic imperatives and objectives with my team to drive execution and growth in the coming months and the years to come. These are five pillars that are going to drive our brand vision for Pedmark, which, again, is a reminder, it's the first and only therapy approved in the U.S. and Europe to reduce the risk of ototoxicity and permanent hearing loss associated with Cisplatin treatments.